BR112013019160A2 - novos compostos, composição farmacêutica, uso, processos e métodos - Google Patents

novos compostos, composição farmacêutica, uso, processos e métodos

Info

Publication number
BR112013019160A2
BR112013019160A2 BR112013019160A BR112013019160A BR112013019160A2 BR 112013019160 A2 BR112013019160 A2 BR 112013019160A2 BR 112013019160 A BR112013019160 A BR 112013019160A BR 112013019160 A BR112013019160 A BR 112013019160A BR 112013019160 A2 BR112013019160 A2 BR 112013019160A2
Authority
BR
Brazil
Prior art keywords
processes
methods
pharmaceutical composition
new compounds
compounds
Prior art date
Application number
BR112013019160A
Other languages
English (en)
Inventor
Kin-Chun Thomas Luk
Michael Soth
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112013019160A2 publication Critical patent/BR112013019160A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

novos compostos, composição farmacêutica, uso, processos e métodos são fornecidos compostos de fórmula i; e os sais farmaceuticamente aceitáveis dos mesmos também são descritos, bem como composições farmacêuticas contendo os referidos compostos e os seus sais farmaceuticamente aceitáveis, e o uso dos referidos compostos e composições farmacêuticas para o tratamento, controle ou melhora da lma.
BR112013019160A 2011-03-17 2012-03-14 novos compostos, composição farmacêutica, uso, processos e métodos BR112013019160A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453601P 2011-03-17 2011-03-17
PCT/EP2012/054415 WO2012123470A1 (en) 2011-03-17 2012-03-14 Imidazo pyrazines

Publications (1)

Publication Number Publication Date
BR112013019160A2 true BR112013019160A2 (pt) 2016-10-04

Family

ID=45855775

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013019160A BR112013019160A2 (pt) 2011-03-17 2012-03-14 novos compostos, composição farmacêutica, uso, processos e métodos

Country Status (12)

Country Link
US (1) US8673905B2 (pt)
EP (1) EP2686319B1 (pt)
JP (1) JP5796094B2 (pt)
KR (1) KR101561756B1 (pt)
CN (1) CN103429593B (pt)
BR (1) BR112013019160A2 (pt)
CA (1) CA2830131A1 (pt)
ES (1) ES2590928T3 (pt)
HK (1) HK1187614A1 (pt)
MX (1) MX340574B (pt)
RU (1) RU2600327C2 (pt)
WO (1) WO2012123470A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9653770B2 (en) 2014-10-21 2017-05-16 At&T Intellectual Property I, L.P. Guided wave coupler, coupling module and methods for use therewith
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
AR106595A1 (es) 2015-11-06 2018-01-31 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
US20170190689A1 (en) 2016-01-05 2017-07-06 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
SG11201908624SA (en) * 2017-04-12 2019-10-30 Magenta Therapeutics Inc Aryl hydrocarbon receptor antagonists and uses thereof
AU2018350980B2 (en) 2017-10-18 2023-02-23 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
US10988477B2 (en) * 2018-01-29 2021-04-27 Merck Patent Gmbh GCN2 inhibitors and uses thereof
LT3847175T (lt) 2018-09-05 2024-03-25 Incyte Corporation Fosfoinozitido 3-kinazės (pi3k) inhibitoriaus kristalinės formos
CN111646978B (zh) * 2020-06-11 2021-12-21 浙江大学 N2-取代烷氧芳环-2-氨基嘧啶类衍生物及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7718801B2 (en) * 2004-08-31 2010-05-18 Banyu Pharmaceutical Co., Ltd. Substituted imidazole derivative
US20070055743A1 (en) 2005-09-02 2007-03-08 Pirtle Ross M Remote control media player
TW200800213A (en) * 2005-09-02 2008-01-01 Abbott Lab Novel imidazo based heterocycles
TW200817410A (en) 2006-08-07 2008-04-16 Incyte Corp Triazolotriazines as kinase inhibitors
EP2084159A1 (en) 2006-10-16 2009-08-05 GPC Biotech Inc. Pyrido ý2, 3-d¨pyrimidines and their use as kinase inhibitors
PE20080931A1 (es) * 2006-11-08 2008-07-19 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP2170892A2 (en) * 2007-06-14 2010-04-07 Schering Corporation Imidazopyrazines as protein kinase inhibitors
TW200942537A (en) * 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
US8507488B2 (en) * 2008-05-13 2013-08-13 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors

Also Published As

Publication number Publication date
EP2686319B1 (en) 2016-07-13
WO2012123470A1 (en) 2012-09-20
EP2686319A1 (en) 2014-01-22
KR101561756B1 (ko) 2015-10-19
US20120238564A1 (en) 2012-09-20
US8673905B2 (en) 2014-03-18
ES2590928T3 (es) 2016-11-24
MX2013010183A (es) 2013-10-03
JP2014508180A (ja) 2014-04-03
MX340574B (es) 2016-07-13
CN103429593A (zh) 2013-12-04
CA2830131A1 (en) 2012-09-20
KR20130133870A (ko) 2013-12-09
CN103429593B (zh) 2015-09-09
JP5796094B2 (ja) 2015-10-21
HK1187614A1 (zh) 2014-04-11
RU2013142881A (ru) 2015-04-27
RU2600327C2 (ru) 2016-10-20

Similar Documents

Publication Publication Date Title
BR112013019160A2 (pt) novos compostos, composição farmacêutica, uso, processos e métodos
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112014033080A2 (pt) inibidores do vírus da hepatite c
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
BR112014030649A2 (pt) inibidores macrocíclicos da flaviviridae vírus
BR112013026834A2 (pt) composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
BR112014013974A8 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112013002375A2 (pt) composto, composição farmacêutica, métodos de tratar um indivíduo para um distúrbio proliferativo de induzir a apoptose das células cancerígenas, e de inibir a atividade de cinase em um mamífero, e, processo de preparação de composto
BR112012017402A2 (pt) inibidores de vírus de flaviviridae
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
BR112014018959A8 (pt) Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer
BR112014002675A2 (pt) "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
BR112015006436A2 (pt) novas piridinonas bicíclicas
ECSP14013215A (es) Compuestos novedosos
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
BR112012023660B8 (pt) usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
BR112013000248A2 (pt) derivados de dióxido de 1,3-propano espirociclicamente substituído, método para a produção dos mesmos e uso dos mesmos como medicamento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]